Gilead Sciences Inc diskutieren
Gilead Sciences Inc
WKN: 885823 / Symbol: GILD / Name: Gilead Sciences / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
118,84 €
-0,45 %
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Leerink Partners from $146.00 to $148.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Rothschild & Co Redburn from $159.00 to $170.00. They now have a "buy" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Mizuho from $140.00 to $170.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Argus from $135.00 to $165.00. They now have a "buy" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $170.00 price target on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its price target raised by Daiwa Securities Group Inc. from $129.00 to $161.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its "buy" rating reaffirmed by Citigroup Inc..
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $180.00 price target on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its price target lowered by Cantor Fitzgerald from $155.00 to $115.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its price target raised by Morgan Stanley from $171.00 to $175.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its price target raised by Citigroup Inc. from $156.00 to $165.00. They now have a "buy" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its price target raised by Morgan Stanley from $171.00 to $175.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its "buy" rating reaffirmed by Truist Financial Corporation. They now have a $157.00 price target on the stock, up from $155.00.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its price target lowered by Daiwa Securities Group Inc. from $161.00 to $150.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) was upgraded by Maxim Group from "hold" to "buy". They now have a $165.00 price target on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its "overweight" rating reaffirmed by Royal Bank Of Canada.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its "overweight" rating reaffirmed by Cantor Fitzgerald. They now have a $155.00 price target on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its "overweight" rating reaffirmed by Cantor Fitzgerald. They now have a $155.00 price target on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its price target lowered by Truist Financial Corporation from $157.00 to $156.00. They now have a "buy" rating on the stock.
Ratings data for GILD provided by MarketBeat
Neueste Beiträge
Morgan_Stanley in Antofagasta plc diskutieren